Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors
Ursa Brown-Glaberman, Alison T StopeckUniversity of Arizona Cancer Center, Tucson, AZ, USAAbstract: Skeletal-related events (SREs) including pain, fractures, and hypercalcemia are a major source of morbidity for cancer patients with bone metastases. The receptor activator of NF-κB liga...
Enregistré dans:
Auteurs principaux: | Stopeck AT, Brown-Glaberman U |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2012
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/3fb737279e1440e4b4da88af4ea2ee9f |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Impact of denosumab on bone mass in cancer patients
par: Brown-Glaberman U, et autres
Publié: (2013) -
Management of bone metastases in refractory prostate cancer – role of denosumab
par: Paller CJ, et autres
Publié: (2012) -
Giant-cell tumor of bone: treatment options and role of denosumab
par: Singh AS, et autres
Publié: (2015) -
Predictors for development of denosumab-induced hypocalcaemia in cancer patients with bone metastases determined by ordered logistic regression analysis
par: Yuko Kanbayashi, et autres
Publié: (2021) -
Denosumab: an investigational drug for the management of postmenopausal osteoporosis
par: E Michael Lewiecki
Publié: (2008)